An official website of the United States government
Home
| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J9011 | Datopotamab Deruxtecan | Datroway | 1mg | Immunotherapy | Drug Antibody Conjugate | Topoisomerase I, TROP2 | No | 2025 | Sep 8, 2025 | In Use | ||
| J9341 | Thiotepa (tepylute) | Tepylute | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard /Ethylenimine | No | 2025 | Jul 9, 2025 | In Use | ||
| J9072 | Cyclophosphamide (frindovyx) | Frindovyx | 5mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2025 | Sep 8, 2025 | In Use | ||
| N/A | Zongertinib | HERNEXEOS | 60mg | Chemotherapy | Tyrosine Kinase Inhibitor | HER2 | Yes | 2025 | In Use | |||
| N/A | Avutometinib potassium and defactinib hydrochloride | AVMAPKI FAKZYNJA CO-PACK | 0.8mg and 200mg | Chemotherapy | MEK Inhibitor, Tyrosine Kinase Inhibitor | MEK1/2, ERK1/2, KRAS | Yes | 2025 | In Use | |||
| C9307 | Linvoseltamab-gcpt | Lynozyfic | 1mg | Immunotherapy | Bispecific Antibody | BCMA, CD3 | No | 2025 | Jan 1, 2026 | In Use | ||
| J9184 | Gemcitabine (avyxa) | Avgemsi | 200mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 2025 | Jan 1, 2026 | In Use | ||
| C9175 | Treosulfan | Grafapex | 50mg | Chemotherapy | Alkylating Agent | Alkyl Sulfonate | No | 2025 | Jul 9, 2025 | Sep 8, 2025 | In Use | |
| N/A | Dordaviprone | MODEYSO | 125mg | Chemotherapy | Protease Activator | ClpP, dopamine D2 | Yes | 2025 | In Use | |||
| C9306 | Telisotuzumab vedotin-tllv | Emrelis | 1mg | Immunotherapy | Drug Antibody Conjugate | c-MET | No | 2025 | 2026 | Sep 8, 2025 | In Use | |
| N/A | Taletrectinib | IBTROZI | 272mg | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, TRKA, TRKB, TRKC | Yes | 2025 | In Use | |||
| Vimseltinib | Romvimza | 14mg, 20mg, 30mg | Chemotherapy | Tyrosine Kinase Inhibitor | CSF1R | Yes | 2025 | In Use | ||||
| Q5159 | Denosumab-dssb | Ospomyv, Xbryk | 1mg | Immunotherapy | Monoclonal Antibody | RANKL | No | 2025 | Sep 8, 2025 | In Use | ||
| N/A | Ensartinib | ENSACOVE | 25mg, 100mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK, ROS1, MET | Yes | 2025 | In Use | |||
| Q5146 | Trastuzumab-strf (hercessi) | Hercessi | 10mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2025 | Jan 1, 2025 | In Use | ||
| J0614 | Treosulfan | Grafapex | 50mg | Chemotherapy | Alkylating Agent | Alkyl Sulfonate | No | 2025 | Sep 8, 2025 | In Use | ||
| J9326 | Telisotuzumab vedotin-tllv | Emrelis | 1mg | Immunotherapy | Drug Antibody Conjugate | c-MET | No | 2025 | Jan 1, 2026 | In Use | ||
| Q5158 | Denosumab-bnht | Bomyntra, Conexxence | 1mg | Immunotherapy | Monoclonal Antibody | RANKL | No | 2025 | Sep 8, 2025 | In Use | ||
| C9308 | Carboplatin (avyxa) | Kyxata | 1mg | Chemotherapy | Alkylating Agent | Platinum Compound | No | 2025 | Jan 1, 2026 | In Use | ||
| Q5160 | Bevacizumab-nwgd (Jobevne) | Jobevne | 10mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2025 | Jan 1, 2026 | In Use | ||
| J9275 | Cosibelimab-ipdl | UNLOXCYT | 2mg | Immunotherapy | Checkpoint Inhibitor | PD-L1 | No | 2025 | Jul 9, 2025 | In Use | ||
| J9282 | Mitomycin Intravesical Instillation | Zusduri | 1mg | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | No | 2025 | Jan 1, 2026 | In Use | ||
| J9289 | Nivolumab and hyaluronidase-nvhy | OPDIVO QVANTIG | 2mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2025 | Jul 9, 2025 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
